Psychiatric Medications

In no way shape or form are we telling patients or prospective clients to stop taking their Psychiatric medications. Intake and moderation of Psychiatric medications is between the patient and the medical professional. Each Individual is different, so our intake process we take a personal approach to helping people get to a fresh new start.

Initial investigation resulted from anecdotal reports of self-treated addicts who experienced a marked lack of desire to continue with opiate abuse following iboga ingestion. Subsequently, ibogaine and 18-methoxycoronaridine have been studied for the treatment of drug addiction.

A radical innovation is psychedelic-assisted psychotherapy (PAP): professionally supervised use of ketamine, MDMA, psilocybin, LSD and ibogaine as part of elaborated psychotherapy programs. Clinical results so far have shown safety and efficacy, even for “treatment resistant” conditions, and thus deserve increasing attention from medical, psychological and psychiatric professionals. But more than novel treatments, the PAP model also has important consequences for the diagnostics and explanation axis of the psychiatric crisis, challenging the discrete nosological entities and advancing novel explanations for mental disorders and their treatment, in a model considerate of social and cultural factors, including adversities, trauma, and the therapeutic potential of some non-ordinary states of consciousness. (Schenberg, 2018)

The addiction model of disease describes the condition as chronic due to long-term changes to the reward centers of the brain. When a person takes ibogaine, the drug is converted into a compound called noribogaine, which targets the areas of the brain affected by drug-seeking and addictive behaviors. Noribogaine “rewires” these areas, allowing the brain to restructure itself to a state similar to before addiction was triggered.